The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tuen Mun Hospital
• Treatments: Etidronic Acid; Risedronate Sodium; Risedronic Acid

Criteria

Inclusion Criteria:

1. Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or equivalent for at least 6 weeks.

2. Age>=18 years and <75 years.

Exclusion Criteria:

1. Pregnant or lactating women.

2. Uncorrected hypocalcemia.

3. History of esophageal stricture.

4. Previous intolerance or hypersenstivity to biphosphonates.